Pierre Raboisson

Chief Executive Officer and Co-founder

Pierre brings over 25 years of leadership in drug discovery and development, with a track record of driving innovation across oncology, immunology, infectious diseases, and neuroscience. Prior to Onco3R, Pierre served as Senior Vice President and Head of Discovery & Preclinical Development at Galapagos, where he reshaped the R&D portfolio to focus on delivering best-in-class medicines. His strategic leadership was instrumental in aligning scientific programs with areas of high unmet medical need and positioning Galapagos for patient-centric innovation. He has also held senior roles at Aligos Therapeutics and Janssen Pharmaceutica (J&J Innovative Medicine), where he led multidisciplinary teams and contributed to the advancement of multiple clinical-stage assets some of them having reached the market. Pierre holds a PharmD and a PhD in Medicinal Chemistry from the University Louis Pasteur in Strasbourg, and completed postdoctoral research at ArQule. He is recognized for his scientific rigor, collaborative mindset, and commitment to developing transformative therapies for patients.